
2022-05-21 13:38:14
Dupixent® Receives FDA Approval to Treat EoE in People Ages 12 and Older
Dupixent® Receives FDA Approval to Treat EoE in People Ages 12 and Older Injection is the first indicated treatment for EoE ...
Find out More2022-06-10 11:45:50
2022-05-21 13:38:14
Dupixent® Receives FDA Approval to Treat EoE in People Ages 12 and Older Injection is the first indicated treatment for EoE ...
Find out More2022-05-13 13:08:56
Atlanta, GA (May 13, 2022) – The American Partnership for Eosinophilic Disorders (APFED) will celebrate the ...
Find out More2022-04-13 12:00:20
(Atlanta, GA) --The Board of Directors of the American Partnership for Eosinophilic Disorders (APFED) has announced the election of a new board officer, James D ...
Find out More2021-12-23 13:41:36
FDA denies approval of TAK-721 (budesonide oral suspension) for EoE Takeda, the pharmaceutical company developing TAK-721 (budesonide oral sus ...
Find out More